2 active not recruiting, 1 not yet recruiting, 1 recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Neuroendocrine Neoplasm: new trials by email Literature Review of Neuroendocrine Neoplasm trials Research Report on Neuroendocrine Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms Somatostatin Analogue(s) - Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm | Phase 3 | Not yet recruiting | Washington University School of Medicine | 240 | 2026-11-30 | 2026-10-19 |
| Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial Somatostatin analog - Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1 | Phase 2 / Phase 3 | Recruiting | The Netherlands Cancer Institute | 39 | 2024-06-25 | 2025-03-03 |
| Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 298 | 2018-10-26 | 2026-10-26 |
| Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate - Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 427 | 2007-12-01 | 2026-10-22 |
Neuroendocrine Tumors (4) · Adenoma, Islet Cell (1) · Carcinoid Tumor (1) · Non functioning pancreatic endocrine tumor (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Adenoma (1) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Neoplasms by Site (1) · Pancreatic Diseases (1)
Acetates (1) · Bevacizumab (1) · Disulfides (1) · Immunoglobulin G (1) · Interferon alpha-2 (1) · Introns (1) · Magnetic Resonance Spectroscopy (1) · Octreotide (1) · Phantoms, Imaging (1) · Salts (1) · Somatostatin (1) · Specimen Handling (1) · X-Rays (1) · cabozantinib (1)
National Cancer Institute (NCI) (2) · The Netherlands Cancer Institute (1) · Washington University School of Medicine (1)
United States (3) · Netherlands (1)
James C Yao (1) · Jennifer A Chan (1) · Nikolaos Trikalinos, MD, MS (1)
PMID 28384065, PMID 33152282, PMID 39282913, PMID 41524552
U10CA032102 (1), U10CA180821 (1), U10CA180888 (1)